Answers are grounded in this paper and cite their sources.
Intracerebral hemorrhage (ICH) lacks proven pharmacotherapies, and behavioral endpoints used in preclinical studies differ in scoring structure and response patterns. We descriptively evaluated three neurological scales—the modified Neurological Severity Score (mNSS), Neurological Deficit Score (NDS), and modified Garcia score (GS)—using edaravone as a reference neuroprotectant. Adult male C57BL/6J mice underwent collagenase-induced ICH or sham surgery and were assigned to Sham, ICH + vehicle, or ICH + edaravone (Eda) groups. The first Eda dose was administered intraperitoneally at 18 h post-ICH, 6 h before the day-1 assessment, followed by daily injections for 7 days. Outcomes included body weight trajectories; histology (Hematoxylin–Eosin), apoptosis (TUNEL), and Western blotting for Bcl-2/Bax at day 3; and longitudinal behavior on days 1, 3, 7, and 14 using mNSS, NDS, and GS. Two blinded raters performed assessments. Total scores and ordinal subscores were analyzed separately using cumulative link mixed-effects models, with group, time, and group × time as fixed effects and animal ID as a random intercept. Odds ratios, 95% confidence intervals, and Bonferroni-adjusted P values were reported. ICH caused early weight loss, perihematomal histological alterations, increased TUNEL-positive cells, and an unfavorable Bcl-2/Bax profile at day 3. Eda was associated with body-weight improvement, less pronounced histological alterations, fewer TUNEL-positive cells, and an increased Bcl-2/Bax ratio. Treatment-associated differences in all three composite scores were observed on days 3 and 7, but not on days 1 or 14. Item-level differences occurred mainly on days 3 and 7, with none remaining significant on days 1 or 14 after multiplicity adjustment. ICH + Eda versus Sham comparisons assessed performance relative to the Sham reference. Edaravone mitigates histological injury and apoptosis and confers domain-specific functional gains after ICH. Among behavioral tools, NDS and mNSS provide greater and more durable to treatment effects, whereas GS is most informative for early, milder deficits. These data support NDS/mNSS as primary endpoints, complemented by targeted GS subscores, to standardize outcome assessment in experimental ICH.
No takes yet. Share an insight, caveat, or question.
Wan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: